4.5 Editorial Material

The full cost and burden of disorders of the brain in Europe exposed for the first time

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 21, 期 10, 页码 715-717

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2011.09.005

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

New psychoactive substances: Pharmacology influencing UK practice, policy and the law

David Nutt

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Article Biochemistry & Molecular Biology

GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513

Tiago Reis Marques, Abhishekh H. Ashok, Ilinca Angelescu, Faith Borgan, Jim Myers, Anne Lingford-Hughes, David J. Nutt, Mattia Veronese, Federico E. Turkheimer, Oliver D. Howes

Summary: The study showed that antipsychotic-free schizophrenia patients have lower levels of alpha 5-GABA(A)Rs in the hippocampus, and there is a significant positive correlation between the levels and PANSS score in these patients.

MOLECULAR PSYCHIATRY (2021)

Review Psychiatry

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Kristoffer A. A. Andersen, Robin Carhart-Harris, David J. Nutt, David Erritzoe

Summary: The systematic review of modern-era clinical studies on serotonergic psychedelics drugs for mental health conditions shows promising treatment efficacy and long-lasting effects in some patients. The safety and feasibility of the studies provide important evidence for the potential of psychedelic therapy as a new treatment avenue for psychiatric conditions.

ACTA PSYCHIATRICA SCANDINAVICA (2021)

Article Biology

Self-blinding citizen science to explore psychedelic microdosing

Balazs Szigeti, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris, David Erritzoe

Summary: The study found that while there were some small but significant differences in emotional state, drug intensity, mood, energy, and creativity between microdosing and placebo groups, these results may be due to participants breaking the blind. Therefore, the study results suggest that the anecdotal benefits of microdosing may be explained by the placebo effect.
Editorial Material Ethics

Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation

S. Rolles, D. J. Nutt, A. K. Schlag

AMERICAN JOURNAL OF BIOETHICS (2021)

Editorial Material Biochemistry & Molecular Biology

Putting the MD back into MDMA

David J. Nutt, Harriet de Wit

Summary: MDMA could be a promising treatment for PTSD according to a phase 3 study, but it will require a shift in perception of this drug.

NATURE MEDICINE (2021)

Review Nutrition & Dietetics

Alcohol and the Brain

David Nutt, Alexandra Hayes, Leon Fonville, Rayyan Zafar, Emily O. C. Palmer, Louise Paterson, Anne Lingford-Hughes

Summary: Alcohol affects the brain in various harmful ways, including damage during intoxication, withdrawal effects, and peripheral factors like poor diet and vitamin deficiencies. Prenatal alcohol exposure can also have lasting impacts on brain development.

NUTRIENTS (2021)

Article Biochemistry & Molecular Biology

Increased global integration in the brain after psilocybin therapy for depression

Richard E. Daws, Christopher Timmermann, Bruna Giribaldi, James D. Sexton, Matthew B. Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harris

Summary: Psilocybin therapy has the potential to treat depression by increasing brain network integration, according to two clinical trials. The antidepressant response to psilocybin was rapid and sustained, while escitalopram had milder effects on brain network organization.

NATURE MEDICINE (2022)

Article Multidisciplinary Sciences

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape

S. Parker Singleton, Andrea I. Luppi, Robin L. Carhart-Harris, Josephine Cruzat, Leor Roseman, David J. Nutt, Gustavo Deco, Morten L. Kringelbach, Emmanuel A. Stamatakis, Amy Kuceyeski

Summary: The authors used network control theory and functional MRI data to show that serotonergic psychedelic drugs like LSD and psilocybin flatten the dynamic landscape of the brain, allowing for easier state transitions and more diverse brain activity over time. These drugs alter subjective experience through serotonin 2a (5-HT2a) receptor agonism, which is associated with increased entropy in brain activity. This increase in entropy is hypothesized to be due to a flattening of the brain's control energy landscape, making transitions between brain states more energy efficient.

NATURE COMMUNICATIONS (2022)

Review Nutrition & Dietetics

Functional Alternatives to Alcohol

David J. Nutt, Robin J. Tyacke, Meg Spriggs, Vanessa Jacoby, Alan D. Borthwick, Delia Belelli

Summary: Alcohol consumption is associated with health harms and governments worldwide are trying to reduce them. One approach is to reduce alcohol consumption, leading to the development of non-alcoholic drinks. However, non-alcoholic drinks do not provide the social interaction that alcohol does. Therefore, the alternative approach is to develop functional drinks that mimic the positive effects of alcohol without the harms.

NUTRIENTS (2022)

Review Biochemistry & Molecular Biology

Imidazoline-I2 PET Tracers in Neuroimaging

Christine A. A. Parker, David J. J. Nutt, Robin J. J. Tyacke

Summary: Targeting neuroinflammation, specifically microglial activation and astrocytosis, is a current focus in the development of new treatment interventions for various neurodegenerative disorders. This review focuses on the recent advancements in the development of I2BS PET tracers that target astrocytes and could serve as clinical imaging tools for neurodegenerative diseases. The review discusses five PET tracers for I2BS, with C-11-BU99008 currently being validated for clinical use and showing potential in revealing early astrogliosis involvement in neurodegeneration.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Editorial Material Neurosciences

Pharmacological Dissection of Antipsychotics

David J. Nutt

BIOLOGICAL PSYCHIATRY (2023)

Editorial Material Pharmacology & Pharmacy

Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins

Balazs Szigeti, Lawrence D. D. Phillips, David Nutt

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Neuroimaging in psychedelic drug development: past, present, and future

Matthew B. Wall, Rebecca Harding, Rayyan Zafar, Eugenii A. Rabiner, David J. Nutt, David Erritzoe

Summary: Psychedelic therapy shows potential for treating psychiatric disorders, but there are still gaps in knowledge regarding the relationship between acute drug effects and long-term outcomes, as well as the impact of these drugs on neuroplasticity. The use of neuroimaging methods can help address these questions and provide a foundation for the development of psychedelic therapy.

MOLECULAR PSYCHIATRY (2023)

Review Psychiatry

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

Otto Simonsson, Per Carlbring, Robin Carhart-Harris, Alan K. Davis, David J. Nutt, Roland R. Griffiths, David Erritzoe, Simon B. Goldberg

Summary: In this meta-analysis of three psilocybin trials for depression, clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (similar to 10%) and for a majority of participants in the waitlist condition (63.6%). The psilocybin arm showed a lower likelihood of symptom worsening versus waitlist, and no difference in the likelihood of symptom worsening versus escitalopram based on the two trials with control arms. Future studies should address the limitation of a relatively small sample size.

PSYCHIATRY RESEARCH (2023)

Article Clinical Neurology

A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS

Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns

Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2024)